Eric B. Lansdon, Ph.D. - Publications

University of California, Davis, Davis, CA 
Structural Biology

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB, Maciejewski P, Rossi AM, Rong H, Macaluso J, Barbosa J, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. Journal of Medicinal Chemistry. 57: 3856-73. PMID 24779514 DOI: 10.1021/jm500228a  0.76
2013 Parrish J, Tong L, Wang M, Chen X, Lansdon EB, Cannizzaro C, Zheng X, Desai MC, Xu L. Synthesis and biological evaluation of phosphonate analogues of nevirapine. Bioorganic & Medicinal Chemistry Letters. 23: 1493-7. PMID 23375792 DOI: 10.1016/j.bmcl.2012.12.049  0.76
2012 Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung M, Samuel D, Novikov N, Xu Y, Mitchell M, Guo H, Babaoglu K, Liu X, Geleziunas R, et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. The Journal of Biological Chemistry. 287: 21189-203. PMID 22535962 DOI: 10.1074/jbc.M112.347534  0.76
2012 Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. Journal of Acquired Immune Deficiency Syndromes (1999). 59: 47-54. PMID 21997204 DOI: 10.1097/QAI.0b013e31823aca74  0.76
2011 Lansdon EB, Liu Q, Leavitt SA, Balakrishnan M, Perry JK, Lancaster-Moyer C, Kutty N, Liu X, Squires NH, Watkins WJ, Kirschberg TA. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrobial Agents and Chemotherapy. 55: 2905-15. PMID 21464257 DOI: 10.1128/AAC.01594-10  0.76
2011 Scarth BJ, White KL, Chen JM, Lansdon EB, Swaminathan S, Miller MD, Götte M. Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 55: 2662-9. PMID 21402840 DOI: 10.1128/AAC.01738-10  0.76
2010 Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. Journal of Medicinal Chemistry. 53: 4295-9. PMID 20438081 DOI: 10.1021/jm1002233  0.76
2010 Lansdon EB, Samuel D, Lagpacan L, Brendza KM, White KL, Hung M, Liu X, Boojamra CG, Mackman RL, Cihlar T, Ray AS, McGrath ME, Swaminathan S. Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. Journal of Molecular Biology. 397: 967-78. PMID 20156454 DOI: 10.1016/j.jmb.2010.02.019  0.76
2010 Mitchell ML, Son JC, Guo H, Im YA, Cho EJ, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Graupe D, Rhodes G, He GX, Geleziunas R, et al. N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters. 20: 1589-92. PMID 20138513 DOI: 10.1016/j.bmcl.2010.01.085  0.76
2010 Mitchell ML, Son JC, Lee IY, Lee CK, Kim HS, Guo H, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Eisenberg G, Geleziunas R, Xu L, et al. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters. 20: 1585-8. PMID 20137928 DOI: 10.1016/j.bmcl.2010.01.086  0.76
2009 Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R. Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex. The Journal of Biological Chemistry. 284: 33580-99. PMID 19801648 DOI: 10.1074/jbc.M109.040121  0.76
2009 Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X, Eisenberg EJ, Jin W, Kutty N, Leavitt S, Liclican A, Liu Q, Liu X, Mak J, Perry JK, ... ... Lansdon EB, et al. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. Journal of Medicinal Chemistry. 52: 5781-4. PMID 19791799 DOI: 10.1021/jm900597q  0.76
2009 Waters JM, O'Neal W, White KL, Wakeford C, Lansdon EB, Harris J, Svarovskaia ES, Miller MD, Borroto-Esoda K. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antiviral Therapy. 14: 231-9. PMID 19430098  0.76
2008 Kirschberg TA, Balakrishnan M, Huang W, Hluhanich R, Kutty N, Liclican AC, McColl DJ, Squires NH, Lansdon EB. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis. Bioorganic & Medicinal Chemistry Letters. 18: 1131-4. PMID 18083512 DOI: 10.1016/j.bmcl.2007.11.127  0.76
2007 Yu Z, Lansdon EB, Segel IH, Fisher AJ. Crystal structure of the bifunctional ATP sulfurylase-APS kinase from the chemolithotrophic thermophile Aquifex aeolicus. Journal of Molecular Biology. 365: 732-43. PMID 17095009 DOI: 10.1016/j.jmb.2006.10.035  0.76
2004 Lansdon EB, Fisher AJ, Segel IH. Human 3'-phosphoadenosine 5'-phosphosulfate synthetase (isoform 1, brain): kinetic properties of the adenosine triphosphate sulfurylase and adenosine 5'-phosphosulfate kinase domains. Biochemistry. 43: 4356-65. PMID 15065880 DOI: 10.1021/bi049827m  0.76
2002 Lansdon EB, Segel IH, Fisher AJ. Ligand-induced structural changes in adenosine 5'-phosphosulfate kinase from Penicillium chrysogenum. Biochemistry. 41: 13672-80. PMID 12427029 DOI: 10.1021/bi026556b  0.76
Show low-probability matches.